Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K5 | Q99683 | 9/20 | 0.42 |
| ▸ | ADORA2A | P29274 | 10/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 10/20 | 0.40 |
| ▸ | BRAF | P15056 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.39 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13498939 | 0.95 | MAP3K5 (0.46) | MAP3K5ADORA2AADORA1BRAFCYP1A2 | |
| SCHEMBL13498837 | 0.95 | MAP3K5 (0.46) | MAP3K5ADORA2AADORA1BRAFCYP1A2 | |
| Trifluoroacetic Acid SCHEMBL3486349 | 0.88 | MAP3K5 (0.43) | MAP3K5 | |
| SCHEMBL13861999 | 0.86 | MAP3K5 (0.49) | MAP3K5ADORA2AADORA1 | |
| Trifluoroacetic Acid SCHEMBL3486629 | 0.85 | MAP3K5 (0.45) | MAP3K5 | |
| Trifluoroacetic Acid SCHEMBL3486253 | 0.84 | CSNK1D (0.43) | MAP3K5 | |
| SCHEMBL13498842 | 0.82 | MAP3K5 (0.47) | MAP3K5 | |
| Trifluoroacetic Acid SCHEMBL3486927 | 0.81 | CSNK1D (0.51) | MAP3K5 | |
| Trifluoroacetic Acid SCHEMBL3485978 | 0.81 | MAP3K5 (0.43) | MAP3K5 | |
| SCHEMBL13498962 | 0.81 | ADORA2A (0.47) | ADORA2AADORA1CYP1A2ADORA3ADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100029619-A1 | FUSED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMTED (JP) | 2010-02-04 | — | — | US | disclosed |
| EP-2058309-A1 | FUSED HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2009-05-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029619-A1 | FUSED HETEROCYCLIC COMPOUND | IRAK1, IL1R1, IRAK2 | MAP3K5 42/4885ADORA2A 1877/4885ADORA1 267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.